Celularity Inc
For the period ended Dec 31, 2024. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed May 8, 2025
CELU$0.76-0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $738 | $227 |
| Accounts receivable, net of allowance of $6,294 and $5,837 as of December 31, 2024 and 2023, respectively | 13,557 | 10,046 |
| Notes receivable | — | 2,072 |
| Inventory | 5,409 | 5,753 |
| Prepaid expenses and other current assets | 857 | 1,695 |
| Total current assets | 20,561 | 19,793 |
| Property and equipment, net | 61,600 | 67,828 |
| Goodwill | 7,347 | 7,347 |
| Intangible assets, net | 9,248 | 11,001 |
| Right-of-use assets - operating leases | 10,830 | 10,990 |
| Restricted cash | 10,239 | 9,936 |
| Inventory, net of current portion | 12,587 | 16,657 |
| Other long-term assets | 270 | 337 |
| Total assets | $132,682 | $143,889 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $23,296 | $14,144 |
| Accrued expenses and other current liabilities | 19,842 | 7,580 |
| Accrued R&D software | — | 3,500 |
| Acquisition-related contingent consideration | 650 | — |
| Short-term debt - unaffiliated (includes debt measured at fair value of $2,485 and $17,223 as of December 31, 2024 and 2023, respectively) | 2,485 | 19,331 |
| Short-term debt - related parties | 3,876 | 19,909 |
| Deferred revenue | 3,531 | 2,834 |
| Total current liabilities | 53,680 | 67,298 |
| Deferred revenue, net of current portion | 2,724 | 3,186 |
| Acquisition-related contingent consideration, net of current portion | 1,413 | 1,606 |
| Long-term debt - related parties | 35,927 | — |
| Long-term lease liabilities | 26,548 | 26,177 |
| Warrant liabilities | 3,264 | 4,359 |
| Deferred income tax liabilities | 9 | 9 |
| Other liabilities | 280 | 294 |
| Total liabilities | 123,845 | 102,929 |
| Commitments and Contingencies (Note 12) | - | - |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized, none issued and outstanding as of December 31, 2024 and 2023 | — | — |
| Common stock, $0.0001 par value, 730,000,000 shares authorized, 22,546,671 and 19,378,192 issued and outstanding as of December 31, 2024 and 2023, respectively | 2 | 19 |
| Additional paid-in capital | 908,523 | 882,732 |
| Accumulated deficit | (899,683) | (841,791) |
| Accumulated other comprehensive loss | (5) | — |
| Total stockholders’ equity | 8,837 | 40,960 |
| Total liabilities and stockholders’ equity | $132,682 | $143,889 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.